Neurocrine nears $2.5 billion deal for Soleno Therapeutics, FT reports

robot
Abstract generation in progress

Neurocrine Biosciences is reportedly close to acquiring Soleno Therapeutics in a deal valued at approximately $2.5 billion, according to an FT report. This brief news item suggests a significant merger and acquisition activity in the pharmaceutical sector. The report from Reuters was published by TradingView.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin